Bavarian Nordic's partner Eurofarma has submitted a regulatory approval application for the chikungunya vaccine CHIKV VLP to Brazil's health agency Anvisa. This marks a key step in making the vaccine available in Brazil, which reports over half of global chikungunya cases and deaths. The vaccine, already approved in the US, Europe, and Canada, is a single-dose, non-infectious vaccine designed for individuals 12 and older. The approval could significantly aid in preventing chikungunya, a mosquito-borne disease causing severe joint pain and chronic symptoms in many patients.
Lyft director Janey Whiteside sold 14,220 shares of the company's stock at a price of $17 per share. This transaction reflects a significant insider sale, which investors often watch as a signal of confidence or strategic portfolio management. The sa...
Broadcom and Lumentum recently posted earnings showing optics are central to AI development. Broadcom's semiconductor solutions revenue surged 79% YoY, with AI semi revenue up 143%, while Lumentum's revenue doubled, driven by optical components and s...
Gold prices approached $4,400 per ounce after US weekly jobless claims exceeded expectations, with 209,000 new claims reported versus the forecasted 202,000. The four-week average of claims also rose slightly, indicating some softness in the labor ma...
Starting August 14, 2026, holders of BOA Acquisition Corp. II units can separate their units to trade Class A ordinary shares and rights individually on Nasdaq under symbols THEO and THEOR. Units not separated will continue trading under THEOU. This ...
Medicus Pharma reported Q2 2026 financial results highlighting progress in its SkinJect and Teverelix drug programs, including FDA and UAE approvals for key studies. The company raised about $40 million through equity and debt in H1 2026, improving i...
